Liver Cancer Therapeutics Market Growth is Driven by Advancements in Precision Medicine, Immunotherapy and Growing Global Incidence.Pune, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Liver Cancer Therapeutics ...

Liver cirrhosis treatment market is estimated to reach approximately $15 billion in the U.S. by 2030Ramat Gan, Israel, Feb. 18, 2025 (GLOBE ...

A newly developed nomogram predicts preoperative microvascular invasion in patients with HCC, improving surgical planning and outcomes.

The US FDA has granted fast track designation to Rznomics' RZ-001 for the treatment of hepatocellular carcinoma (HCC).

Hepatocellular carcinoma (HCC) is one of the deadliest malignant tumors in the world, and its incidence and mortality have ...

Announcing a new publication for Acta Materia Medica journal. Icaritin (ICA) is a prenylflavonoid natural product extracted from plants of the Epimedium genus.

This study investigated the long-term prognosis and clinical course of patients who survived for more than 5 years after hepatocellular carcinoma (HCC) diagnosis.This retrospective cohort study used ...

Primary Biliary Cholangitis Clinical Trial Pipeline Pharmaceutical companies are advancing the Primary Biliary Cholangitis treatment pipeli ...

In a challenging market environment, NAYA stock has touched a 52-week low, with shares plummeting to $0.35. According to InvestingPro data, the company's financial health score is rated as WEAK, with ...

U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for ...